Physician profile
Mena Milad
NPI 1912265968
$4,262.30
in general payments reported to CMS, 2019-2025
23 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,095 · 2020: $287 · 2021: $261 · 2022: $263 · 2023: $558 · 2024: $536 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,356.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,405.95 | 2019-2025 | |
| Boston Scientific Corporation | $546.88 | 2019-2023 | Watchman Access System |
| Madrigal Pharmaceuticals | $415.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $359.43 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $246.42 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.02 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $173.95 | 2020-2022 | |
| Genzyme Corporation | $164.09 | 2023-2025 | |
| Echosens North America, INC. | $141.24 | 2023 | Fibroscan |
| Erbe USA INC | $108.27 | 2019-2023 | Erbe Vio3 |
| Pfizer INC. | $102.09 | 2022-2025 | |
| Medtronic, INC. | $79.84 | 2021 | |
| Neuraxis, INC. | $76.14 | 2025 | |
| Phathom Pharmaceuticals, INC. | $55.73 | 2025 | Voquezna |
| Janssen Biotech, INC. | $40.54 | 2023-2024 | Stelara, Simponi Aria, Simponi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $33.72 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $27.28 | 2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $25.00 | 2025 | Iqirvo |
| Novo Nordisk INC | $22.09 | 2025 | Wegovy |
| Enterra Medical, INC. | $18.94 | 2022 | |
| Capsovision, INC. | $15.45 | 2025 | Capsocam Plus |
| Nestle Healthcare Nutrition INC. | $15.18 | 2021 | |
| Braintree Laboratories, INC. | $14.31 | 2023 | Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mena Milad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.